Skip to main content
Log in

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

It is generally thought that future advances in the treatment and cure of breast cancer patients will be made possible through a deeper understanding of tumor biology and an improved capability to define the prognosis of each single patient. This will lead to the formulation of new, more selective, and patient-tailored therapies. It is therefore important, when studying potential prognostic factors, to follow methodologic requirements and guidelines which involve the carrying out of prospective studies as confirmatory steps. Repeatedly or recently investigated prognostic markers (tumor size, menopausal status, ER, PgR, 3H thymidine labeling index, c-erbB-2 and p27 expression) were evaluated on a series of 286 prospectively recruited node negative breast cancer patients who underwent loco-regional treatment alone and were closely followed. The individual and relative prognostic contribution of each variable with respect to other factors, as well as their ability to identify node negative patients at risk, were assessed by univariate and multivariate analysis. At a five-year follow-up, only tumor size (p = 0.021) and TLI (p = 0.016) individually proved to be significant prognostic indicators of relapse-free survival. Conversely, p27 expression was not related to RFS and c-erbB-2 expression appeared to have only a short-term effect on patient prognosis. TLI and tumor size, tested in multivariate analysis along with ER and menopausal status, maintained their independent prognostic relevance. The study, performed on a large series of node-negative patients given loco-regional treatment alone, for the first time prospectively recruited, showed the prognostic relevance of TLI and its independence from other clinico-pathologic and biologic factors over a five-year period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Gass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG: Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 14: 1982–1992, 1996

    PubMed  Google Scholar 

  2. Zambetti M, Valagussa P, Bonadonna G: Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Ann Oncol 7: 481–485, 1996

    PubMed  Google Scholar 

  3. The Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491–496, 1989

    Google Scholar 

  4. Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320: 485–490, 1989

    PubMed  Google Scholar 

  5. Kerr JF, Wyllie AH, Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257, 1972

    PubMed  Google Scholar 

  6. Fraser A, Evan G: A licence to kill. Cell 85: 781–784, 1996

    PubMed  Google Scholar 

  7. Salvesen G, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell 91: 443–446, 1997

    Article  PubMed  Google Scholar 

  8. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 82(1): 4–6, 1990

    PubMed  Google Scholar 

  9. Folkman J: Angiogenesis and breast cancer. J Clin Oncol 12(3): 441–443, 1994

    PubMed  Google Scholar 

  10. Zhou P, JiangW, Weghorst CM, Weinstein IB: Overexpression of cyclin D1 enhances gene amplification. Cancer Res 56(1): 36–39, 1996

    PubMed  Google Scholar 

  11. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB related gene in a human mammary carcinoma. Science 229: 974–976, 1985

    PubMed  Google Scholar 

  12. Akijama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644–1646, 1986

    PubMed  Google Scholar 

  13. KrausMH, IssingW, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci 86: 9193–9197, 1989

    PubMed  Google Scholar 

  14. Klÿn JGM, Berns PMJJ, Schmitz PIM, Foekeus JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13: 156–170, 1992

    Google Scholar 

  15. Gullick WJ, Srinivasan R: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 52: 43–53, 1998

    PubMed  Google Scholar 

  16. Stephens RW, Brünner N, Jänicke F, Schmitt M: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 52: 99–111, 1998

    PubMed  Google Scholar 

  17. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene (Review article). Nature 351: 453–456, 1991

    PubMed  Google Scholar 

  18. Chang F, Syrjanen S, Syrjanen K: Implication of the p53 tumor suppressor gene in clinical oncology. J Clin Oncol 13: 1009–1022, 1995

    PubMed  Google Scholar 

  19. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in node-negative breast cancers. J Nat Cancer Inst 85: 965–970, 1993

    PubMed  Google Scholar 

  20. Silvestrini R, Daidone MG, Del Bino G, Mastore M, Di Fronzo G, Boracchi P: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Ann Oncol 4: 213–219, 1993

    PubMed  Google Scholar 

  21. Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in nodenegative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986

    PubMed  Google Scholar 

  22. Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadori B, Veronesi U: Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11: 1150–1155, 1993

    PubMed  Google Scholar 

  23. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Squicciarini P, Orefice S, Salvadori B: 3Hthymidine labeling index as a prognostic indicator in nodepositive breast cancer. J Clin Oncol 8: 1321–1326, 1990

    PubMed  Google Scholar 

  24. Silvestrini R, The SICCAB Group for quality control of cell kinetic determination: Feasibility and reproducibility of the 3H-TdR labeling index in breast cancer. Cell Prolif 21: 437–445, 1991

    Google Scholar 

  25. Piffanelli A, Pellizzola D, Giovannini G, Catozzi L, Faggioli L, Giganti M: Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation of breast cancer biopsies. Tumori 75: 550–556, 1989

    Google Scholar 

  26. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  27. Cox DR: Regression models and life tables. J Roy Stat Soc 34: 187–220, 1972

    Google Scholar 

  28. Lawless JS: Statistical models and methods for life-time data. Wiley, New York, 1982

    Google Scholar 

  29. SAS Institute Inc: SAS/STAT User's Guide, version 6, 4th ed., vol. 1. Cary, NC: SAS Institute, 1989

    Google Scholar 

  30. Gentili C, Sanfilippo O, Silvestrini R: Cell proliferation in relation to clinical features and relapse in breast cancers. Cancer 48: 974–979, 1981

    PubMed  Google Scholar 

  31. Silvestrini R, Daidone MG, Luisi A, Mastore M, Leutner, Salvadori B: Cell proliferation in 3800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer 74: 122–127, 1997

    PubMed  Google Scholar 

  32. Tubiana M, Pejovic MH, Chavandra G, Contesso G, Malaise EP: The long term prognostic significance of the thymidine labeling index in breast cancer. Int J Cancer 33: 441–445, 1984

    PubMed  Google Scholar 

  33. Meyer JS, Friedman E, Mc Crote MM, Bauer WC: Prediction of early course of breast carcinoma by thymidine labeling. Cancer 51: 1879–1886, 1983

    PubMed  Google Scholar 

  34. Hery M, Gioanni J, Lalanne CM, Namer M, Coudri A: The DNA labeling index: a prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9: 207–212, 1987

    PubMed  Google Scholar 

  35. Meyer JS, Province M: Proliferative index of breast cancer by thymidine labeling index: prognostic power independent of stage, estrogen and progesteron receptors. Breast Cancer Res Treat 12: 191–199, 1988

    PubMed  Google Scholar 

  36. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G: Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25: 1165–1171, 1989

    PubMed  Google Scholar 

  37. Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labeling index versus estrogen receptors and tumor size in nodenegative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986

    PubMed  Google Scholar 

  38. Mangia A, Picciarello M, Tommasi S, Simone G, Barletta A, Longo S, De liso M, D'Errico D, Schittulli F, Catino AM, Paradiso A, De Lena M: Fattori prognostici nel carcinoma della mammella operabile N-: attività proliferativa e caratteristiche clinico-patologiche. Folia Oncologica 14: 247–253, 1991

    Google Scholar 

  39. Tubiana M, Pejovic MH, Koscienly S, Chavandra N, Malaise E: Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 44: 17–22, 1987

    Google Scholar 

  40. Silvestrini R, Daidone MG, Gasparini G: Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer 56: 1982–1987, 1985

    PubMed  Google Scholar 

  41. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Veronesi U: Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 13: 697–704, 1995

    PubMed  Google Scholar 

  42. Révillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791–808, 1998

    PubMed  Google Scholar 

  43. Kallionemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor-long term survival in breast cancer. Int J Cancer 49: 650–655, 1991

    PubMed  Google Scholar 

  44. Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Reiner G, Preis PN: Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 120: 737–742, 1994

    PubMed  Google Scholar 

  45. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44–49, 1991

    PubMed  Google Scholar 

  46. Delarue JC, Terrier P, Terrier-Lacombe MJ, Mouriesse H, Gotteland M, May-Levin F: Combined overexpression of cerbB-2 protein and epidermal growth factor receptor (EGR-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study. Bull Cancer 81: 1067–1077, 1994

    PubMed  Google Scholar 

  47. De Potter CR, Beghin C, Makar AP, Vandekerckhove D, Roels HJ: The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients. Int J Cancer 45: 55–58, 1990

    PubMed  Google Scholar 

  48. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between cerbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444–446, 1991

    PubMed  Google Scholar 

  49. Kommos F, Colley M, Hart CE, Franklin WA: In situ distrubution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-β-subunit. Mol Cell Probes 4: 11–23, 1990

    PubMed  Google Scholar 

  50. Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WJ, Elston CW, Blaney RW: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63: 439–443, 1991

    PubMed  Google Scholar 

  51. Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB-2 overexpression in axillary lymph node positive breast cancer. tiResults from a randomized adjuvant treatment protocol. Cancer 74: 2956–2963, 1994

    PubMed  Google Scholar 

  52. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR: Relationship between c-erbB-2 immunoreactivity and thymidine labeling index in breast carcinoma in situ. Breast Cancer Res Treat 18: 11–17, 1991

    PubMed  Google Scholar 

  53. Contegiacomo A, Pizzi C, De Marchis L, Alimandi M, Delrio P, Di Palma E, Petrella G, Ottini L, French D, Frati L, Bianco AR, Mariani-Costantini R: High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers. Int J Cancer 61(1): 1–6, 1995

    PubMed  Google Scholar 

  54. Slamon DJ, Godolphin W, Jones LA Holt JA, Wong SG, Keith DE, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989

    PubMed  Google Scholar 

  55. Thor AD, Schwartz LH, Koerner FC Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Paniali DL, Marks PJ, Fingert HJ, et al.: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147–7152, 1989

    PubMed  Google Scholar 

  56. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Bürki K, Castiglione M, Collins J, Lindtner J, Senn H-J for the International (Ludwig) Breast Cancer Study Group: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049–1056, 1992

    PubMed  Google Scholar 

  57. Gasparini G, Widner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454–466, 1994

    PubMed  Google Scholar 

  58. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-posivite early breast cancer. N Engl J Med 330: 1260–1266, 1994

    Article  PubMed  Google Scholar 

  59. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, Mc Guire WL: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599–605, 1992

    PubMed  Google Scholar 

  60. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver KL, Hurd SD, Stewart SJ: p185 c-erbB-2 signalling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54: 3758–3765, 1994

    PubMed  Google Scholar 

  61. Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer; therapeutic implications. Oncology (Huntingt) 11(Suppl 2): 43–48, 1997

    Google Scholar 

  62. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135, 1995

    PubMed  Google Scholar 

  63. Stål O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A: 185–190, 1995

    Google Scholar 

  64. Tan P, Cady B, WannerM, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res 57: 1259–1263, 1997

    PubMed  Google Scholar 

  65. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227–230, 1997

    Article  PubMed  Google Scholar 

  66. Wu J, Shen Z-Z, Jiang M, Han Q-N, Fontana JA, Barsky SH Shao ZM: Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 79: 1572–1578, 1999

    PubMed  Google Scholar 

  67. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 2: 222–225, 1997

    Google Scholar 

  68. Reed W, Florenes WA, Holm R, Hannisdal E, Nesland JN: Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 435: 116–124, 1999

    PubMed  Google Scholar 

  69. Sulkes A, Livingstone RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 62: 513–515, 1979

    PubMed  Google Scholar 

  70. Daidone MG, Silvestrini R, Canova S, Valagussa P: Tumor cell kinetics and course of node-positive (N+) breast cancer (Abstract). Proc Am Soc Clin Oncol 8: 24, 1989

    Google Scholar 

  71. Zambetti M, Bonadonna G, Valagussa P, Daidone MG, Coradini D, Bignami P, Contesso G, Silvestrini R: Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer. NCI Monograph 11: 77–83, 1992

    Google Scholar 

  72. Gardin G, Alama A, Rosso R, Campora E, Repetto L, Pronzato P, Merlini L, Naso C, Camoriano A, Meazza R: Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32: 311–318, 1994

    PubMed  Google Scholar 

  73. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Casadei Giunchi D, Vio A, Saragoni A, Silvestrini R: Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 43: 7–14, 1997

    PubMed  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volpi, A., Paola, F.D., Nanni, O. et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 63, 181–192 (2000). https://doi.org/10.1023/A:1006464426977

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006464426977

Navigation